Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avycaz vs Meropenem for Nosocomial Pneumonia
NCT01808092Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2013
- Primary completion
- Jan 2016
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of ceftazidime + avibactam in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), sponsored by Pfizer. Primary endpoint: Clinical Cure at Test-of-cure. Started Apr 2013; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT01808092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808092.